p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate.
about
Emerging critical role of molecular testing in diagnostic genitourinary pathologyp53 independent, region-specific epithelial apoptosis is induced in the rat epididymis by deprivation of luminal factors.A prospective pilot evaluation of urinary and immunohistochemical markers as predictors of clinical stage of urothelial carcinoma of the bladder.Down-regulation of Cdc6, a cell cycle regulatory gene, in prostate cancer.BRAF activation initiates but does not maintain invasive prostate adenocarcinomaXPA-210: a new proliferation marker to characterize tumor biology and progression of renal cell carcinoma.Recent advances in the histopathology and molecular biology of prostate cancer.Differential regulation of androgen and glucocorticoid receptors by retinoblastoma protein.Insulin receptor isoforms A and B as well as insulin receptor substrates-1 and -2 are differentially expressed in prostate cancer.Prognostic factors in prostate cancer.Genes differentially expressed in prostate cancer.Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10.Prostate tumours from an Asian population: examination of bax, bcl-2, p53 and ras and identification of bax as a prognostic marker.The role of stress proteins in prostate cancer.Using molecular markers to help predict who will fail after radical prostatectomy.NUSAP1 expression is upregulated by loss of RB1 in prostate cancer cells.Regulatory BCL2 promoter polymorphism (-938C>A) is associated with adverse outcome in patients with prostate carcinoma.Role of E2F3 expression in modulating cellular proliferation rate in human bladder and prostate cancer cells.Molecular markers for predicting prostate cancer stage and survival.Androgen stimulated cellular proliferation in the human prostate cancer cell line LNCaP is associated with reduced retinoblastoma protein expression.The retinoblastoma protein regulates hypoxia-inducible genetic programs, tumor cell invasiveness and neuroendocrine differentiation in prostate cancer cells.Phosphorylation of Fas-associated death domain contributes to enhancement of etoposide-induced apoptosis in prostate cancer cells.Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome.p53 and cyclooxygenase-2 expression are directly associated with cyclin D1 expression in radical prostatectomy specimens of patients with hormone-naïve prostate cancer.Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells.[Therapy of castration-resistant prostate cancer]Q57135350
P2860
Q27021371-3A1D9DA3-27D1-451C-84B2-433520B59A01Q30303991-341F0160-D5B4-489F-8B5E-0D20E3D24DEEQ30305730-D157E85A-FF39-4AAC-9584-FCF970D8383AQ32107802-554F72FB-362E-4FB2-BED2-E321BC6DF095Q33392719-D9E2378A-7DD3-42F3-84E9-DBC67772ED39Q33757520-3B046A43-BFD9-41DB-8EF4-80247218EBBBQ33808366-51DE9F12-864D-4088-9E15-58FF8DD7F458Q34067885-28055649-7753-4197-B149-C5598B7EBC0AQ34515985-6C4B89F1-1A8C-4AB7-82B8-DF8B8AF9DBC1Q34682069-F2FCC7D1-F34E-4930-A5A1-0AAC417D4B1DQ35772604-AC01FD07-4FD6-4CC4-A996-EE116AD1269DQ35946094-0C9F8D95-8662-412B-879D-83B2D5E37676Q36621908-0144E497-6A56-45FA-85F6-35E44F2DB152Q37223453-D9C40661-A7AE-47FE-927E-BBB876011845Q37957896-4952E3EB-D044-4C9A-B4A9-3A7564E6E5B3Q38920403-77DE646E-42BB-4C38-9C2B-BF0EF78A90E4Q39612017-DAC5F1BA-A5F2-4DB7-A2C1-AAE34A36FF3CQ40243680-93F7697E-44DB-485F-AC67-2CBEB0FE86F4Q40739742-659A1358-9041-4100-A651-F9EB2D3DA193Q40762889-7A30BE0E-7A90-4957-B5F8-D25F95120384Q41134167-12FD7F3D-23DF-4FF0-B5AE-5749CF809681Q43656322-2554FA67-2426-4D42-B552-65A86736AE2AQ43882042-2E0B66F3-5037-4410-ABDB-8980D6E50E29Q45262425-7C8DAFBF-54A7-44DB-A3E6-CACA22E95023Q47761529-761462EB-975C-404B-A708-7E81F9BBE0C7Q57133648-DC7BC102-EE02-4556-AA2A-D55C76CF4E6AQ57135350-62444D79-CD89-4616-9DD2-CE816FEAA090
P2860
p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate.
description
1997 nî lūn-bûn
@nan
1997 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
name
p53, bcl-2 and retinoblastoma ...... zed carcinoma of the prostate.
@ast
p53, bcl-2 and retinoblastoma ...... zed carcinoma of the prostate.
@en
type
label
p53, bcl-2 and retinoblastoma ...... zed carcinoma of the prostate.
@ast
p53, bcl-2 and retinoblastoma ...... zed carcinoma of the prostate.
@en
prefLabel
p53, bcl-2 and retinoblastoma ...... zed carcinoma of the prostate.
@ast
p53, bcl-2 and retinoblastoma ...... zed carcinoma of the prostate.
@en
P2093
P1476
p53, bcl-2 and retinoblastoma ...... zed carcinoma of the prostate.
@en
P2093
Frierson HF Jr
Theodorescu D
P304
P356
10.1097/00005392-199707000-00040
P407
P577
1997-07-01T00:00:00Z